Whalesbook
Yeh mamla Novo Nordisk aur Dr. Reddy's Laboratories ke beech ek trademark dispute ka hai, aur isse pata chalta hai ki India public health ko IP rights se upar kaise rakhta hai, khaas kar jab baat diabetes jaise essential drugs ki ho.
Court Ka Faisla: 30 Din Tak Bikega Drug
Delhi High Court ne March 30, 2026 ko ek bada hi subtle decision diya. Court ne mana ki Dr. Reddy's ka 'OLYMVIQ' naam Novo Nordisk ke 'Ozempic' ko infringe karta hai, matlab naam mein similarity hai jo customers ko confuse kar sakti hai. Pehle toh Dr. Reddy's ko is brand ki sales aur marketing band karne ko kaha gaya tha.
Lekin, final order mein Justice Jyoti Singh ne public interest ko priority di. Dr. Reddy's Laboratories ko permissions hai ki woh apni semaglutide injection 'OLYMVIQ' ka jo stock abhi unke paas hai, woh 30 din tak bech sakte hain. Aur agar 30 din baad bhi koi stock bach jaata hai, toh use destroy karne ki jagah government hospitals mein donate karna hoga. Court ka kehna tha ki drug ko barbaad karne se behtar hai ki woh patients tak pahunche.
Chunki Dr. Reddy's ne pehle hi announce kar diya tha ki woh 'OLYMVIQ' ki jagah naya brand 'Olymra' launch karenge, aur Novo Nordisk ne isse accept bhi kar liya tha, toh asal issue bas existing inventory ka tha. Dr. Reddy's ne yeh bhi bataya tha ki drug temperature-sensitive hai, jisse immediate destruction ya relabeling mushkil ho sakta hai.
India: IP Aur Public Health Ka Balance
Yeh ruling India ke standard approach ko dikhati hai, jahan strong intellectual property protection ke saath-saath affordable medicines ki access bhi zaroori hai. India ko isi wajah se 'Pharmacy of the Global South' bola jaata hai. Patent laws mein provisions hain jaise Section 3(d) jo patent evergreening ko rokte hain, aur compulsory licensing allow karte hain, sab public health ko dhyan mein rakhte hue.
Market Ka Scene
Semaglutide drugs ka global market bahut tezi se badh raha hai, diabetes aur obesity cases badhne ki wajah se. Ye market $93 billion tak pahunchne ka estimate hai 2035 tak. Ozempic ismein ek major player hai. Novo Nordisk toh diabetes care mein global leader hai aur Ozempic se zabardast revenue kama raha hai.
India mein bhi diabetes drug market $2.16 billion tak pahunchna expected hai 2031 tak. Halanki, India mein generics ke competition aur patent expiry ke baad, Novo Nordisk ko Ozempic aur Wegovy ke prices 48% tak kam karne pade hain. Isse affordability aur market access ka importance pata chalta hai.
Dono Companies Ke Liye Challenges
Dr. Reddy's ko relief toh mil gaya, par naye brand 'Olymra' ko launch karne mein re-branding, marketing aur inventory management ka kharcha aayega. Court ka infringement find karna bhi future mein challenges khade kar sakta hai.
Novo Nordisk ke liye, India mein price cuts aur Indian generics se competition market share aur profit margins par pressure bana raha hai. Stock ratings bhi 'Hold' ki taraf jaa rahe hain.
Lekin, overall yeh ruling India ke framework ko reinforce karti hai ki kaise pharma IP rights ko patients ki health needs ke saath balance kiya jaata hai. Aise decisions dusre countries ke liye bhi template ban sakte hain.